Workflow
滚动市盈率
icon
Search documents
伟思医疗收盘上涨1.70%,滚动市盈率39.32倍,总市值44.60亿元
Sou Hu Cai Jing· 2025-07-30 12:15
Company Overview - Weisi Medical's closing price on July 30 was 46.57 yuan, with an increase of 1.70%, resulting in a rolling PE ratio of 39.32 times and a total market value of 4.46 billion yuan [1] - The company operates in the medical device sector, focusing on the research, production, and sales of medical devices, including magnetic stimulation, electrical stimulation, electrophysiology, consumables, and laser radiofrequency products [1] Financial Performance - For the first quarter of 2025, Weisi Medical reported revenue of 95.91 million yuan, representing a year-on-year increase of 9.40% [1] - The net profit for the same period was 33.22 million yuan, showing a significant year-on-year growth of 52.71% [1] - The sales gross margin stood at 66.65% [1] Industry Comparison - The average PE ratio for the medical device industry is 55.15 times, with a median of 37.48 times, positioning Weisi Medical at the 78th rank within the industry [1] - The company has one institutional holder, which is a fund, holding a total of 90,000 shares valued at 0.04 million yuan [1] - The industry average market value is 11.57 billion yuan, indicating that Weisi Medical's market value is significantly lower than the industry average [2]
迈瑞医疗收盘上涨2.65%,滚动市盈率25.91倍,总市值2885.13亿元
Sou Hu Cai Jing· 2025-07-30 10:15
Group 1 - The core viewpoint of the articles highlights that Mindray Medical's stock price closed at 237.96 yuan, with a PE ratio of 25.91, marking a new low in 84 days, and a total market capitalization of 288.51 billion yuan [1] - The average PE ratio for the medical device industry is 55.15, with a median of 37.48, positioning Mindray Medical at the 51st rank within the industry [1] - As of March 31, 2025, the number of shareholders for Mindray Medical increased to 92,191, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Mindray Medical's main business includes the research, manufacturing, marketing, and service of medical devices, with key products in life information and support, in vitro diagnostics, medical imaging, electrophysiology, and vascular intervention [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 8.237 billion yuan, a year-on-year decrease of 12.12%, and a net profit of 2.629 billion yuan, down 16.81%, with a gross profit margin of 62.53% [1] - The PE ratios of other companies in the medical device industry range from 11.07 to 20.21, with Mindray Medical's PE ratio being significantly lower than the industry average [2]
开立医疗收盘上涨1.22%,滚动市盈率279.09倍,总市值140.33亿元
Sou Hu Cai Jing· 2025-07-30 10:15
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kaili Medical, indicating a significant decline in revenue and profit in the latest quarter, alongside a high PE ratio compared to industry averages [1][2] - As of July 30, Kaili Medical's stock closed at 32.43 yuan, with a PE ratio of 279.09, marking a new low in 35 days, and a total market capitalization of 14.033 billion yuan [1] - The medical device industry has an average PE ratio of 55.15, with Kaili Medical ranking 118th among its peers, indicating a relatively high valuation compared to the industry [1][2] Group 2 - In the first quarter of 2025, Kaili Medical reported an operating income of 430 million yuan, a year-on-year decrease of 10.29%, and a net profit of 8.0746 million yuan, down 91.94% year-on-year, with a gross margin of 63.19% [2] - The company specializes in the research, development, production, and sales of medical diagnostic and treatment equipment, with a strong focus on ultrasound diagnostic devices and other minimally invasive surgical products [1] - Kaili Medical has over 20 years of experience in the ultrasound industry, being one of the first companies in China to develop and master core technologies for color ultrasound machines, holding a significant market share domestically and ranking tenth globally [1]
麦克奥迪收盘下跌3.25%,滚动市盈率51.54倍,总市值84.80亿元
Sou Hu Cai Jing· 2025-07-30 09:52
从行业市盈率排名来看,公司所处的电网设备行业市盈率平均36.50倍,行业中值40.24倍,麦克奥迪排 名第102位。 股东方面,截至2025年3月31日,麦克奥迪股东户数35773户,较上次减少315户,户均持股市值35.28万 元,户均持股数量2.76万股。 7月30日,麦克奥迪今日收盘16.39元,下跌3.25%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到51.54倍,总市值84.80亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13麦克奥迪51.5452.524.5884.80亿行业平均 36.5040.823.7194.62亿行业中值40.2443.052.7948.59亿1炬华科技11.2212.281.9881.65亿2新联电子 12.3618.111.4148.29亿3正泰电器12.6112.881.16498.99亿4三星医疗12.7613.462.42304.21亿5金杯电工 12.8813.341.8575.89亿6海兴电力14.3113.271.83132.94亿7友讯达15.4313.792.6027.32亿8柘中股份 17.2886.082.2062 ...
纽威数控收盘上涨2.98%,滚动市盈率20.92倍,总市值66.31亿元
Jin Rong Jie· 2025-07-29 11:20
Group 1 - The core business of the company is the research, production, and sales of mid-to-high-end CNC machine tools, including large machining centers, vertical CNC machines, and horizontal CNC machines [2] - As of March 31, 2025, the company had 11,793 shareholders, a decrease of 431 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company achieved a revenue of 569 million yuan in the first quarter of 2025, representing a year-on-year increase of 3.80%, while net profit was 61.36 million yuan, a year-on-year decrease of 11.78%, with a gross profit margin of 21.11% [2] Group 2 - The company's current price-to-earnings (PE) ratio is 20.92, which is significantly lower than the industry average of 78.79 and the industry median of 44.05, ranking 63rd in the general equipment industry [1][3] - The company has received multiple accolades, including recognition as a Jiangsu Province Intelligent Manufacturing Factory and a Jiangsu Province Five-Star Cloud Enterprise, among others [2] - The company has been awarded the CNAS certificate for its testing laboratory, indicating compliance with national standards [2]
南京商旅收盘下跌1.15%,滚动市盈率118.79倍,总市值37.49亿元
Sou Hu Cai Jing· 2025-07-29 10:13
Company Overview - Nanjing Commercial Travel Co., Ltd. focuses on commercial trade and tourism, with main products including textiles, machinery, chemical raw materials, metal materials, non-metallic minerals, tourism services, and general retail [1] - As of March 31, 2025, the company had 30,086 shareholders, a decrease of 906 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - For Q1 2025, the company reported revenue of 191 million yuan, a year-on-year decrease of 7.98%, and a net profit of 3.51 million yuan, down 80.03% year-on-year, with a gross profit margin of 22.30% [1] - The current stock price is 12.07 yuan, down 1.15%, with a rolling PE ratio of 118.79 times, and a total market capitalization of 3.749 billion yuan [1] Industry Comparison - The average PE ratio for the trade industry is 47.62 times, with a median of 38.89 times, positioning Nanjing Commercial Travel at the 33rd rank within the industry [1][2] - The industry average market capitalization is 9.521 billion yuan, while the median is 7.918 billion yuan [2]
可孚医疗收盘上涨1.01%,滚动市盈率25.63倍,总市值77.41亿元
Sou Hu Cai Jing· 2025-07-29 09:56
Core Viewpoint - Cofoe Medical's stock closed at 37.02 yuan, with a rolling PE ratio of 25.63 times, and a total market value of 7.741 billion yuan, indicating a relatively lower valuation compared to the industry average [1][2]. Company Overview - Cofoe Medical specializes in the research, production, sales, and service of medical devices, with a diverse product range including blood glucose systems, blood pressure monitors, and various medical consumables [2]. - The company has received several accolades, including recognition as a potential brand in the Chinese retail pharmaceutical market for 2023-2024 and being listed among the key trademark protection catalog in Changsha [2]. Financial Performance - In the first quarter of 2025, Cofoe Medical reported revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.425 million yuan, down 9.68%, with a gross profit margin of 52.17% [2]. Industry Comparison - The average PE ratio for the medical device industry is 55.46 times, with a median of 37.74 times, positioning Cofoe Medical at the 51st rank within the industry [1][3]. - Cofoe Medical's PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [3].
中电港收盘上涨1.91%,滚动市盈率58.60倍,总市值158.44亿元
Jin Rong Jie· 2025-07-29 09:29
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhongdian Port, with a closing price of 20.85 yuan and a PE ratio of 58.60 times, indicating a strong market position within the trade industry [1][2] - Zhongdian Port's total market capitalization is reported at 15.844 billion yuan, ranking 28th in the trade industry based on PE ratio, which has an average of 47.62 times and a median of 38.89 times [1][2] - The company experienced a net outflow of main funds amounting to 2.6682 million yuan on July 29, with a total outflow of 35.3139 million yuan over the past five days, indicating a trend of capital withdrawal [1] Group 2 - Zhongdian Port's main business includes electronic component distribution, design chain services, supply chain collaboration, and industrial data services, with key products being memory, processors, analog devices, and RF/wireless connections [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating revenue of 17.470 billion yuan, representing a year-on-year increase of 49.01%, and a net profit of 84.5551 million yuan, up 64.99% year-on-year, with a gross profit margin of 2.66% [1]
乐普医疗收盘上涨1.10%,滚动市盈率204.42倍,总市值293.56亿元
Sou Hu Cai Jing· 2025-07-29 09:12
来源:金融界 乐普(北京)医疗器械股份有限公司的主营业务是医疗器械、药品、医疗服务及健康管理。公司的主要产 品是医疗器械、药品、医疗服务及健康管理。 最新一期业绩显示,2025年一季报,公司实现营业收入17.36亿元,同比-9.67%;净利润3.79亿元,同 比-21.44%,销售毛利率64.03%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13乐普医疗204.42118.881.91293.56亿行业平均 55.4650.344.76115.47亿行业中值37.7437.642.7056.85亿1九安医疗10.9411.070.86184.69亿2英科医疗 13.3414.381.19210.74亿3新华医疗15.3914.261.2598.65亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2816.331.87154.02亿6奥美医疗16.3015.971.6858.89亿7康德莱17.0517.061.4136.73亿8九强生物 17.6216.382.1687.24亿9奥泰生物18.0719.051.4657.63亿10维力医疗18.5919.332.1842.4 ...
东华能源收盘下跌2.85%,滚动市盈率35.30倍,总市值155.56亿元
Sou Hu Cai Jing· 2025-07-29 08:37
Group 1 - The core viewpoint of the articles indicates that Donghua Energy's stock is underperforming compared to its industry peers, with a current PE ratio of 35.30, significantly higher than the industry average of 13.08 [1][2] - Donghua Energy's market capitalization stands at 15.556 billion yuan, ranking 14th in the oil industry based on PE ratio [1][2] - The company experienced a net outflow of 29.02 million yuan in principal funds on July 29, with a total outflow of 76.7369 million yuan over the past five days [1] Group 2 - The latest financial report for Donghua Energy shows a revenue of 7.980 billion yuan for Q1 2025, reflecting a year-on-year increase of 12.18%, while net profit decreased by 5.68% to 52.585 million yuan [1] - The gross profit margin for the company is reported at 4.72% [1] - In comparison to other companies in the oil sector, Donghua Energy's PE ratio is significantly higher than the industry average and median, indicating potential overvaluation [2]